La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Society Pass a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Society Pass..

Society Pass (NASDAQ:SOPA) Azioni, Catena delle Opzioni

Society Pass

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with visionary entrepreneurs, the company meets the growing demand for better services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food and grocery deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Merchant Point of Sale (merchant POS). The company generates the majority of its revenue from the Digital marketing segment.

Society Pass Inc

<p>Shares of <strong>Expedia Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) are climbing following reports <a href="https://www.benzinga.com/news/24/10/41383838/expedia-shares-rises-by-around-6-whats-going-on">of a potential buyout.</a></p>
<p>With the stock now overbought, there's a strong chance it could reverse and trend lower. That&#8217;s why our team of trading experts has selected it as our Stock of the Day.</p>
<p>Typically, a stock remains within its usual trading range. However, when investors and traders turn emotional and aggressively buy, they can drive the price above this range. In such cases, the stock is considered &#8220;overbought.&#8221;</p>
<p>Many trading strategies and styles are based on the concept of reversion to the mean. If a stock is overbought, people may start to sell it and this could push the price lower.</p>
<p>There are dozens if not hundreds of ways to measure momentum. They are called indicators. It is important to understand that they are different ways of measuring the same thing. New traders can overcomplicate things by studying too many of them.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a></strong></p>
<p>Some traders have had success by using and mastering just a few of these indicators.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp" alt="" class="wp-image-638424" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1024x530.webp 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-300x155.webp 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-768x397.webp 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart-1536x795.webp 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08144115/expe-chart.webp 1585w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>The red line on the chart is called a Bollinger Band. It is two standard deviations above the 20-day moving average. This is important because according to statistics and probability theory, 95% of all trading should be within two standard deviations of the mean.</p>
<p>If a stock exceeds this threshold, as Expedia has done, it will draw sellers into the market. They will be expecting a reversion back towards the average and their selling could put pressure on it.</p>
<p>On the bottom part of the chart is the Relative Strength Index (RSI). It is another way to measure momentum. If the blue line exceeds the horizontal red line, it indicates overbought conditions. As you can see, that is the case now. This could also draw sellers into the market.</p>
<p>Other popular momentum indicators include Moving Average Convergence Divergence (MACD), the Commodity Channel Index (CCI), and Stochastics (TAS). These are all available on <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p>Many rookie traders make things more complicated than they need to be. Part of this is using too many indicators. It may make sense for some traders to only use a few and to become familiar and comfortable with them.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41849984/powell-brushes-off-trumps-removal-threat-economists-say-2026-could-be-his-last-stand">Powell Brushes Off Trump&#8217;s Removal Threat: Economists Say 2026 Could Be His Last Stand</a></strong></li>
</ul>
<p><em>Photo: II.studio/Shutterstock.com</em></p>


Technicals

Travel

Trading Ideas

EXPE

Stock Of The Day: Expedia Appears Overbought And May Reverse

WIIM

GATO

GOLD

PAAS

SAND

SBSW

Shares of metals and materials companies are trading lower. The sector may be reacting to China's recent stimulus efforts which have struggled to buoy the economy and business conditions.

<p>In the current session, the stock is trading at $116.60, after a <strong>0.46%</strong> increase. Over the past month, <strong>e.l.f. Beauty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>)</strong> stock increased by <strong>8.49%</strong>, and in the past year, by <strong>22.36%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731095785_0.png" alt="Past Year Chart" /></p>

<h3>Comparing e.l.f. Beauty P/E Against Its Peers</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of <strong>49.61</strong> in the Personal Products industry, e.l.f. Beauty Inc. has a higher P/E ratio of <strong>62.74</strong>. Shareholders might be inclined to think that e.l.f. Beauty Inc. might perform better than its industry group. It's also possible that the stock is overvalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1731095785_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


News

Intraday Update

Markets

A Look Into e.l.f. Beauty Inc's Price Over Earnings

Salesforce shares are trading higher after the company announced it will hire 1,000 people for an "AI product sales push" and is also developing artificial intelligence agents.

<p>Merck (NYSE:&nbsp;MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has recommended WINREVAIR&#xAE; (sotatercept) for reimbursement in combination with standard pulmonary arterial hypertension (PAH) therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class (FC) II or III.</p>
<p>Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada, a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.</p>


Global

Merck Announces That Canada's Drug Agency Has Recommended WINREVAIR For Reimbursement In Combination With Standard Pulmonary Arterial Hypertension Therapy, For The Treatment Of Adults With World Health Organization Group 1 PAH And Functional Class II Or III

Gray Television shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, the company said it's carefully evaluating capital expenditure needs for 2025 and announced its board approved an increase in its debt repurchase authorization.

<p>TD Cowen  analyst Andrew Charles   maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Hold and raises the price target from $18 to $21.</p>


Price Target

Analyst Ratings

FWRG

TD Cowen Maintains Hold on First Watch Restaurant Gr, Raises Price Target to $21

DVAX

Dynavax Technologies shares are trading higher after the company reported better-than-expected Q3 EPS results and launched a $200 million share buyback program. HC Wainwright & Co. reiterated a Buy rating on the stock.

<p>Benchmark  analyst Robert Wasserman   maintains Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) with a Buy and raises the price target from $110 to $135.</p>


LGND

Benchmark Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $135

<p><a href="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push" title="https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push">https://www.bloomberg.com/news/articles/2024-11-08/salesforce-to-hire-1-000-salespeople-for-ai-agent-push</a></p>
<p>&nbsp;</p>
<p>Salesforce Inc. plans to hire more than 1,000 workers to sell its new generative AI agent product.&nbsp;</p>


Management

"Salesforce To Hire 1,000 People For AI Product Sales Push; Company To Take Advantage Of AI 'Momentum,' CEO Says; Rivals Also Developing Artificial Intelligence Agents" - Bloomberg News

<p>HC Wainwright &amp; Co.  analyst Emily Bodnar   maintains Arcellx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) with a Buy and raises the price target from $95 to $115.</p>


ACLX

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $115

<p><strong>We revise our guidance</strong></p>
<p>Due to higher-than-expected inflation in the second half of the year, we have revised our year-end inflation forecast upwards. Accordingly, we are updating our revenue growth target5 for 2024 to approximately 7%. We maintain our EBITDA margin expectation at approximately 42% and our operational capex to sales6 ratio target at approximately 23%.</p>
<p>I extend my heartfelt thanks to all our employees for their contributions to our success and express my gratitude to our Board of Directors for their continued support.</p>
<p>(1) EBITDA is a non-GAAP financial measure. See page 14 for the explanation of how we calculate Adjusted EBITDA and its reconciliation to net income<br /><br />(2) Excluding M2M<br /><br />(3) Following the change in organizational structure, the revenues of Turkcell Sigorta Aracılık Hizmetleri A.Ş. (Insurance Agency), which was previously managed under Financell, are now classified as "Other" in the Techfin segment as of the first quarter of 2023.<br /><br />(4) Including IPTV, OTT TV, fizy, lifebox and GAME+<br /><br />(5) Our expectations for 2024 incorporate the effects of inflation accounting under IAS 29. These projections are based on assumptions regarding factors beyond our control, including key macroeconomic indicators such as inflation. Specifically, we are assuming an annual inflation rate of 43%, applied on a monthly basis, (previous estimate: 37%). This paragraph contains forward-looking statements that reflect our current estimates and expectations regarding market conditions across all of our businesses. However, there can be no assurance that these forward-looking statements will occur as anticipated. For a discussion of the various factors that could impact the outcome of these forward-looking statements, please refer to our 2023 annual report on Form 20-F filed with the SEC, specifically the risk factors section.<br /><br />(6) Excluding license fees</p>


Guidance

Turkcell Iletisim Hizmetleri On Thursday November 7, 2024 Said Due To Higher-Than-Expected Inflation In The 2H Of The Year, Have Revised Our Year-End Inflation Forecast Upwards; Updating Our Revenue Growth Target For 2024 To ~ 7%. We Maintain Our EBITDA Margin Expectation At ~ 42% And Our Operational CapEx To Sales Ratio Target At ~ 23%

<p>Needham  analyst James Ricchiuti   maintains nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) with a Buy and raises the price target from $15 to $16.</p>


LASR

Needham Maintains Buy on nLight, Raises Price Target to $16

<p>Deep-pocketed investors have adopted a bearish approach towards Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AAPL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 27 extraordinary options activities for Apple. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 48% bearish. Among these notable options, 8 are puts, totaling $387,928, and 19 are calls, amounting to $1,239,539.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $240.0 for Apple, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Apple's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Apple's whale trades within a strike price range from $100.0 to $240.0 in the last 30 days. </p>
<h3>Apple 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094737_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.45</td>
<td>$7.35</td>
<td>$7.45</td>
<td>$230.00</td>
<td>$312.0K</td>
<td>30.6K</td>
<td>487</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.0</td>
<td>$129.6</td>
<td>$130.0</td>
<td>$100.00</td>
<td>$117.0K</td>
<td>489</td>
<td>24</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$3.5</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$225.00</td>
<td>$100.5K</td>
<td>12.0K</td>
<td>948</td>
</tr>
<tr>
<td>AAPL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$5.15</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$230.00</td>
<td>$91.7K</td>
<td>972</td>
<td>189</td>
</tr>
<tr>
<td>AAPL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.09</td>
<td>$2.08</td>
<td>$2.08</td>
<td>$227.50</td>
<td>$83.3K</td>
<td>7.5K</td>
<td>8.1K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Apple</h3>
<p>Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.</p>
<h3>Current Position of Apple</h3>
<ul>
<li>With a trading volume of 14,296,721, the price of AAPL is down by -0.18%, reaching $227.07.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Apple</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $224.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays has decided to maintain their Underweight rating on Apple, which currently sits at a price target of $184.<br />
&#x2A; An analyst from Keybanc has revised its rating downward to Underweight, adjusting the price target to $200.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Apple, which currently sits at a price target of $262.<br />
&#x2A; An analyst from Maxim Group persists with their Hold rating on Apple, maintaining a target price of $215.<br />
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $260. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Apple options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

AAPL

What the Options Market Tells Us About Apple

<p>6 analysts have shared their evaluations of OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated OrthoPediatrics and provided 12-month price targets. The average target is $39.67, accompanied by a high estimate of $50.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.82%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094736_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A clear picture of OrthoPediatrics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to OrthoPediatrics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OrthoPediatrics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of OrthoPediatrics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into OrthoPediatrics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/KIDS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on OrthoPediatrics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind OrthoPediatrics</h2>
<p>OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.</p>
<h3>Understanding the Numbers: OrthoPediatrics's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining OrthoPediatrics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>3.35%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> OrthoPediatrics's net margin excels beyond industry benchmarks, reaching <strong>-14.51%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> OrthoPediatrics's ROE excels beyond industry benchmarks, reaching <strong>-2.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-1.72%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> OrthoPediatrics's debt-to-equity ratio is below the industry average at <strong>0.2</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


KIDS

The Latest Analyst Ratings For OrthoPediatrics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>GE Vernova</strong>.</p>
<p>Looking at options history for GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 38% with bearish.</p>
<p>From the overall spotted trades, 2 are puts, for a total amount of $303,024 and 11, calls, for a total amount of $1,151,800.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $345.0 for GE Vernova over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for GE Vernova's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of GE Vernova's whale trades within a strike price range from $150.0 to $345.0 in the last 30 days. </p>
<h3>GE Vernova 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094732_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$91.0</td>
<td>$89.0</td>
<td>$91.0</td>
<td>$250.00</td>
<td>$364.0K</td>
<td align="right">309</td>
<td align="right">40</td>
</tr>
<tr>
<td>GEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$20.7</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$340.00</td>
<td>$207.0K</td>
<td align="right">4</td>
<td align="right">101</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$310.00</td>
<td>$206.0K</td>
<td align="right">16</td>
<td align="right">40</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$60.0</td>
<td>$59.0</td>
<td>$60.0</td>
<td>$300.00</td>
<td>$198.0K</td>
<td align="right">199</td>
<td align="right">33</td>
</tr>
<tr>
<td>GEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$70.9</td>
<td>$69.2</td>
<td>$69.2</td>
<td>$300.00</td>
<td>$138.4K</td>
<td align="right">59</td>
<td align="right">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Vernova</h3>
<p>GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.</p>
<p>Following our analysis of the options activities associated with GE Vernova, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is GE Vernova Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,430,176, with GEV's price down by -0.32%, positioned at $335.24.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 11 days.</li>
</ul>
<h3>Expert Opinions on GE Vernova</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $307.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on GE Vernova with a target price of $308.<br />
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on GE Vernova, which currently sits at a price target of $285.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on GE Vernova, maintaining a target price of $301.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on GE Vernova with a target price of $325.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on GE Vernova, maintaining a target price of $320. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest GE Vernova options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Check Out What Whales Are Doing With GEV

<p>Deep-pocketed investors have adopted a bullish approach towards Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SPOT usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Spotify Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 47% leaning bullish and 39% bearish. Among these notable options, 3 are puts, totaling $239,975, and 20 are calls, amounting to $1,741,376.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $380.0 to $465.0 for Spotify Technology over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Spotify Technology's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Spotify Technology's whale activity within a strike price range from $380.0 to $465.0 in the last 30 days. </p>
<h3>Spotify Technology Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731094727_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$32.35</td>
<td>$30.55</td>
<td>$31.4</td>
<td>$390.00</td>
<td>$178.9K</td>
<td>4.4K</td>
<td align="right">260</td>
</tr>
<tr>
<td>SPOT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$24.0</td>
<td>$23.1</td>
<td>$23.8</td>
<td>$410.00</td>
<td>$178.5K</td>
<td>15</td>
<td align="right">75</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$32.55</td>
<td>$30.55</td>
<td>$31.4</td>
<td>$390.00</td>
<td>$175.8K</td>
<td>4.4K</td>
<td align="right">165</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.05</td>
<td>$30.6</td>
<td>$31.75</td>
<td>$390.00</td>
<td>$161.9K</td>
<td>4.4K</td>
<td align="right">400</td>
</tr>
<tr>
<td>SPOT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$32.15</td>
<td>$30.55</td>
<td>$31.7</td>
<td>$390.00</td>
<td>$148.9K</td>
<td>4.4K</td>
<td align="right">349</td>
</tr>
</tbody>
</table>
</p>
<h3>About Spotify Technology</h3>
<p>Spotify is the leading global music streaming service provider, with over 600 million monthly active users and 250 million paying subscribers, with the latter comprising the firm's premium segment. most of the firm's revenue and nearly all its gross profit come from the subscribers, who pay a monthly fee to access a very comprehensive music library that consists of most of the most popular songs ever recorded, including all from the major record labels. The firm also sells separate audiobook subscriptions and integrates podcasts within its standard music app. Podcast content is not exclusive and is typically free to access on other platforms. Ad-supported users can access a similar music catalog but cannot customize a similar on-demand experience.</p>
<p>Having examined the options trading patterns of Spotify Technology, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Spotify Technology Standing Right Now?</h3>
<ul>
<li>With a trading volume of 798,576, the price of SPOT is up by 0.58%, reaching $402.17.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 4 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Spotify Technology</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $453.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Spotify Technology, targeting a price of $470.<br />
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Spotify Technology, which currently sits at a price target of $490.<br />
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Spotify Technology, which currently sits at a price target of $438.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Spotify Technology, which currently sits at a price target of $430.<br />
&#x2A; Consistent in their evaluation, an analyst from Deutsche Bank keeps a Buy rating on Spotify Technology with a target price of $440. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Spotify Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


SPOT

Looking At Spotify Technology's Recent Unusual Options Activity

<p>Benchmark  analyst Cody Acree   reiterates Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and maintains $9 price target.</p>


Reiteration

INDI

Benchmark Reiterates Buy on Indie Semiconductor, Maintains $9 Price Target

<p><strong>Pinterest, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) stock is moving lower Friday after the company reported worse-than-expected <a href="https://www.benzinga.com//node/41827920">third-quarter earnings. </a></p>
<p><strong>What To Know:</strong> Pinterest stock fell approximately 12% after the bell on Thursday following the earnings report and continues to trade lower on Friday.</p>
<p>The company reported earnings per share of 4 cents missing analyst estimates of 7 cents. In addition, it reported sales of $898 million beating analyst estimates of $896.34 million. </p>
<p>Pinterest provided a more detailed look into its revenue. It reported revenue of $719 million from the U.S. and Canada, $137 million from Europe and $42 million from the rest of the world.</p>
<p>The company also reported some important business metrics. Pinterest announced Average Revenue Per User (ARPU) of $1.70 and Global Monthly Active Users (MAUs) of 537 million. </p>
<p>&#8220;Our AI investments are driving results by powering better personalized experiences and greater performance for advertisers, with our lower-funnel ad tools being the fastest-growing part of our business. Advertisers are increasingly relying on Pinterest to engage our growing audience who see us as a great place to find inspiration, curate and shop,&#8221; said CEO of Pinterest <strong>Bill Ready</strong>.</p>
<p>Pinterest issued guidance for the 2024 fourth-quarter, which may be weighing on the stock. It anticipates revenue between $1.12 billion and $1.14 billion versus analyst estimates of $1.14 billion.</p>
<p><strong>Analyst Changes:</strong> Following the earnings report, multiple analysts issued <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/41850902/pinterest-reports-healthy-q3-q4-guidance-disappoints-6-analysts-cut-forecasts-while-looking-for-ai-to-drive-1h25">price target changes.</a></p>
<p><strong>Related Link: <a href="https://www.benzinga.com/markets/equities/24/11/41795194/cathie-woods-wednesday-exodus-moderna-and-jack-dorseys-block-stocks-get-dumped">Cathie Wood&#8217;s Wednesday Exodus: Moderna And Jack Dorsey&#8217;s Block Stocks Get Dumped</a></strong></p>
<p><strong>PINS Price Action:</strong> At the time of publication, Pinterest stock is moving 15.9% lower at $28.55, per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Image via Shutterstock</em></p>


Movers

PINS

What's Going On With Pinterest Shares Friday?

<p>The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. </p>
<p>According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. </p>
<p>This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.</p>
<p><strong>Bristol-Myers Squibb &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. </p>
<p><strong>Gilead Sciences Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.</p>
<p><strong>Sanofi SA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. </p>
<p>Similarly, <strong>AbbVie Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.</p>
<p><strong>Alnylam Pharmaceuticals Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. </p>
<p><strong>Roche Holdings AG's </strong>(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.</p>
<p>On the downside, Wegovy maker <strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.</p>
<p>Similarly, <strong>Eli Lilly &amp; Co</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. </p>
<p><strong>Merck &amp; Co Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.</p>
<p>&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why"><strong>ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</strong></a></li>
</ul>
<p><em>Image Via Shutterstock</em></p>


Biotech

Large Cap

Health Care

General

ABBV

ALNY

GILD

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Warning: SOPA is at high risk of performing badly

Society Pass regains compliance with Nasdaq minimum closing bid price rule

In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Society Pass (SOPA – Research Report). The company's shares...

Maxim Group Remains a Hold on Society Pass (SOPA)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Making millions through the stock market is only possible in a few ways. Investors need one of these three things: </p>



<ul><li>Massive sums of capital to begin with</li>



<li>Decades of time and more modest sums of capital</li>



<li>More modest sums of capital and a combination of risk and luck</li>
</ul><p>We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. </p>



<p>Investing in sub-$2 stocks is very risky. Direct the majority of your capital toward more stable, conservative approaches. Direct much less capital to these riskier stocks that will require a combination of risk and luck.</p>



<p>All of the stocks discussed below cost less than $2 per share meaning $1,000 will get you at least 500 shares. Those 500 or more shares have the potential to appreciate in value above $10,000 by 2025.</p>



<h2>Reliance Global (RELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div><p><strong>Reliance Global</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/reli-stock-quote/"><strong>RELI</strong></a></span>) is a business group that acquires and manages retail insurance agencies in the United States. I chose to lead off the article with this stock specifically because it is not a pharma firm or another biotech stock. The purpose in doing so is not to say that <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are bad. Instead, it is to show there are plenty of 10X <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> outside of the biotech sector.</p>



<p>As I mentioned, there is a lot of risk in investing in shares of stocks trading at these levels. Investing in Reliance Global will be no different. The stock has lost roughly 95% of its value over the last 12 months. It currently trades for 25 cents per share. That should logically raise a lot of red flags for investors. However, there are reasons to believe that the company can rebound from here. </p>



<p>Primarily, the company recently announced a definitive agreement to acquire <strong>Spetner Associates</strong>. The integration of Spetner Associates is expected to double Reliance Global&rsquo;s annual revenues to $28 million.&nbsp;</p>



<p>That news was <a href="https://www.globenewswire.com/news-release/2024/05/15/2882429/0/en/Reliance-Global-Group-Announces-Game-Changing-Acquisition-of-Spetner-Associates-Projected-to-Double-Company-s-Revenue.html">announced on May 15</a> and sent share prices drastically higher. The bet at this time is the integration of the new partner will again significantly increase revenues. Despite the obvious risk, that&rsquo;s the clear narrative behind investing in Reliance Global.</p>



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div><p><strong>aTyr Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/life-stock-quote/"><strong>LIFE</strong></a></span>) is a biotech stock focused on the treatment of lung diseases that lead to fibrosis, or scarring of the lung tissue.</p>



<p>It appears to be among the better biotech stocks to bet on at this time. The company&rsquo;s lead candidate drug, Efzofitimod, has received FDA and EU orphan drug designation. That effectively fast tracks its development for the treatment of sarcoidosis and scleroderma.</p>



<p>The company also has a deal in place with Japan&rsquo;s <strong>Kyorin Pharmaceutical</strong> worth up to $175 million To develop and commercialize Efzofitimod in Japan. The company&rsquo;s pipeline of drugs extends beyond Efzofitimod with that drug being the clear catalyst overall.&nbsp;</p>



<p>LIFE shares currently trade for $1.76 and <a href="https://stockanalysis.com/stocks/life/forecast/">have a consensus target price above $25</a>.&nbsp;</p>



<p>The company continues to release <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-positive-dsmb-review-efzofitimod">positive news about its lead candidate drug</a>. That is not the only good news surrounding aTyr Pharma. The company also announced inducement grants that allowed <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-4">two employees to purchase 9,400 shares of stock at $1.86</a>. That suggests there is an immediate upside in LIFE stock at the moment.</p>



<h2>BioLineRx (BLRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div><p><strong>BioLineRx</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/blrx-stock-quote/"><strong>BLRX</strong></a></span>) is a company attempting to commercialize therapeutics for the treatment of various cancers and rare diseases including sickle cell disease. The company&rsquo;s recent announcements around those projects deserve particular attention and make the stock attractive.</p>



<p>BioLineRx truly does look like a biotech stock that&rsquo;s about to move much higher. Interested investors should read this <a href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html">recent portfolio update from May 28</a>. The company&rsquo;s FDA-approved multiple myeloma treatment, Aphexda, is growing steadily in its first full quarter of post-approval adoption.&nbsp;</p>



<p>The drug is quickly making its way into the network of transplant centers and is placed at 26% of all institutions in the U.S. currently. BioLineRx expects that number to rise to 35% by the end of the second quarter and could rise to 60% by the end of the year.</p>



<p>The biotech is currently running at a slight net loss of $0.7 million but benefits from continued progress in clinical trials relating to other diseases including sickle cell disease. In short, there seem to be multiple reasons to bet on BLRX stock at the moment.</p>



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div><p><strong>Knightscope</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/kscp-stock-quote/"><strong>KSCP</strong></a></span>) stock represents a company that builds fully autonomous security robots. Honestly, its products look a bit like something out of a dystopian future movie from the &rsquo;90s. Despite that, Knightscope&rsquo;s progress makes it very interesting for investors.</p>



<p>The company hasn&rsquo;t released highly detailed financial statements but the most recent indication that we have is from March. That report <a href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-2023-estimated-revenues-increase-128-128-million">showed revenues increased by 128% to $12.8 million </a>during 2023. The report also includes some images of the company&rsquo;s AI-enabled security robots that are a bit cyberpunk and Robocop.&nbsp;</p>



<p>The company released another report days later updating the company&rsquo;s financial position. It showed that the company&rsquo;s net loss narrowed from $25.6 million to $22.1 million in 2023. It also noted the company has 10,000 machines in its network across the United States and the company plans to reduce its payroll expense by 30% this year.</p>



<p>The company has since <a href="https://ir.knightscope.com/news-and-events/news">won multiple contracts and deployed multiple tranches </a>of robots.&nbsp;</p>



<h2>Adial Pharmaceuticals (ADIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Adial Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/adil-stock-quote/"><strong>ADIL</strong></a></span>) is a company working to address addiction disorders that are quite rampant across society. The reason to believe in the stock lies in its lead candidate drug, AD04. That drug is intended to treat alcohol use disorder, opioid use disorder and a host of potential other drug dependencies.&nbsp;</p>



<p>The company has identified a range of genetic phenotypes that respond to AD04. Adial Pharmaceuticals estimates that represents a $40 billion opportunity in the U.S. alone.</p>



<p>The company also secured patent rights protecting the ability of that drug to target specific gene sequences relating to various drug dependency disorders.&nbsp;</p>



<p>The company is clearly very interesting for its positioning relative to various substance dependencies and their overall socioeconomic burden. However, potential investors should also be aware the company&rsquo;s&nbsp;current liquidity only covers the company through the first quarter of 2025. Regardless, substance disorder pharmaceutical firms are a rapidly growing sub-sector within the industry and Adial Pharmaceuticals could certainly emerge as a winner.&nbsp;</p>



<h2>Society Pass (SOPA)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div><p>Investors interested in the outsized growth prospects in Southeast Asia should take a look at <strong>Society Pass</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sopa-stock-quote/"><strong>SOPA</strong></a></span>). The company continues to build an ecosystem encompassing e-commerce and fintech worth understanding at least.</p>



<p>The <a href="https://www.globenewswire.com/news-release/2023/12/07/2792494/0/en/Society-Pass-Inc-Nasdaq-SOPA-Ascendiant-Capital-Issues-3Q-2023-Equity-Research-Update-3Q-Results-Show-Solid-Revenue-Growth-and-Maintains-Positive-Outlook-on-Growth-Prospects.html">most recent earnings report</a> from the third quarter of 2023 shows that revenues grew by 11%. Clearly, that&rsquo;s not the sort of outsized growth many seek from emerging market opportunities. Nevertheless, there are things to like about Society Pass. What I like is that the company has zero debt and $8 million in cash.&nbsp;&nbsp;</p>



<p>Despite a net loss of $3.9 million in the period, the company managed to report a modest gross profit of $600,000. The company also has a $40 million line of credit should that ultimately be necessary. That line of credit is an indication institutional investors see the overall opportunity represented by Society Pass. Much like Adial Pharmaceutical, Society Pass is interesting for operating within a high-growth sub-sector that may not get as much attention as it deserves.</p>



<h2>Enviva (EVA)</h2>



<div><img width="300" height="200" src="https://investorplace.com/wp-content/uploads/2022/01/carbon-dioxide-1600-300x200.png" alt="Environmental pollution, environmental problem, smoke from the chimney of an industrial plant or thermal power plant against a cloudy sky"><div>Source: AYDO8 / Shutterstock.com</div></div><p>Investing in<strong> Enviva</strong> (NYSE:<span><a href="https://investorplace.com/stock-quotes/eva-stock-quote/"><strong>EVA</strong></a></span>) stock will appeal to green investors&nbsp;and industrial investors looking for turnaround opportunities. The company produces sustainable wood pellets intended to provide a low-carbon alternative to fossil fuels.</p>



<p>While the company has some interesting, promising catalysts, it is going through a transition as it attempts to affect a turnaround. The most recent earnings reports &mdash; from November 2023 &mdash; gets into those details.</p>



<p>Most of the report focused on the appointment of the company&rsquo;s previous CFO to an interim CEO position. He is essentially tasked with turning around deepening losses and righting the course for Enviva. The <a href="https://ir.envivabiomass.com/news/news-details/2023/Enviva-Reports-3Q-2023-Results/default.aspx">fundamentals tell the story of a company in trouble</a>. Revenues fell by a modest 1.3% in that report while net losses more than quadrupled to $85.2 million.&nbsp;</p>



<p>The company has <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001592057/5aee415d-4604-4366-a34d-18c777395a61.pdf">not filed any subsequent financial reports</a> since November. It&rsquo;s clearly at risk of bankruptcy and restructuring. My sense is that the company&rsquo;s shares will trend downward but they certainly do <a href="https://stockanalysis.com/stocks/eva/forecast/">have the potential to 10X</a> nonetheless.&nbsp;</p>



<p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.</em></p>



<p><strong><em>Read More:&nbsp;</em></strong><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/"><em>Penny Stocks &mdash; How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com </em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em>Publishing Guidelines</em></a><em>.</em></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/06/millionaire-makers-7-stocks-you-can-buy-for-2-that-can-10x-by-2025/">Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

The latest announcement is out from Society Pass (SOPA). Society Pass Incorporated witnessed a shift in its leadership as board members John Mackay...

Society Pass Leadership Overhaul and Board Expansion

Society Pass (SOPA) just unveiled an update. Jeremy Miller and Tan Bien Kiat have stepped down from their roles as directors of Society Pass Incorp...

Society Pass Announces Amicable Board Reshuffle

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are a hot topic as we dive into all of the biggest news traders need to know about on Monday morning!</p>



<p>Moving stocks this morning are an acquisition deal, a strategic alliance, earnings data and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Tellurian</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tell-stock-quote/"><strong>TELL</strong></a>) stock is rocketing more than 66% <a href="https://finance.yahoo.com/news/tellurian-acquired-woodside-approximately-900-222900949.html">due to a $900 million acquisition deal</a>.</li>



<li><strong>Serve Robotics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/"><strong>SERV</strong></a>) shares are soaring over 60% after <strong>Nvidia </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/"><strong>NVDA</strong></a>) <a href="https://investorplace.com/2024/07/serv-stock-soars-as-nvidia-reveals-big-bet-on-serve-robotics/">revealed a stake in the company</a>.</li>



<li><strong>Castellum </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/"><strong>CTM</strong></a>) stock is surging more than 56% after <a href="https://www.nasdaq.com/press-release/castellum-inc-announces-strategic-alliance-k2-2024-07-22">announcing a strategic alliance</a>.</li>



<li><strong>Netcapital </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/"><strong>NCPL</strong></a>) shares are rising over 40% alongside heavy pre-market trading.</li>



<li><strong>Richtech Robotics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/"><strong>RR</strong></a>) stock is increasing more than 27% after <a href="https://www.nasdaq.com/press-release/richtech-robotics-celebrates-completion-installation-adam-ghost-kitchens-inside">adding ADAM to certain ghost kitchens</a>.</li>



<li><strong>CISO Global</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/"><strong>CISO</strong></a>) shares are gaining over 24% after announcing <a href="https://www.nasdaq.com/press-release/ciso-global-announces-solution-mitigate-impact-crowdstrike-security-event-2024-07-19">a way to mitigate damage</a> from the <strong>CrowdStrike </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/"><strong>CRWD</strong></a>) issues last week.</li>



<li><strong>Tellurian Inc. 8.25% Senior Notes due 2028</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/telz-stock-quote/"><strong>TELZ</strong></a>) are heading more than 21% higher this morning.</li>



<li><strong>Nuzee </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/"><strong>NUZE</strong></a>) stock is climbing over 18% without any clear news this morning.</li>



<li><strong>Society Pass</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/"><strong>SOPA</strong></a>) shares are jumping more than 17% on Monday morning.</li>



<li><strong>TuanChe </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/"><strong>TC</strong></a>) stock is up over 16% without any clear news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Exicure </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/"><strong>XCUR</strong></a>) stock is plummeting more than 24% after a major rally on Friday.</li>



<li><strong>Sentage </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/"><strong>SNTG</strong></a>) shares are diving over 14% on Monday morning.</li>



<li><strong>Sonoma Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/"><strong>SNOA</strong></a>) stock is tumbling close to 14% this morning.</li>



<li><strong>Novo Integrated Sciences</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/"><strong>NVOS</strong></a>) shares are taking a nearly 14% beating after <a href="https://investorplace.com/earning-results/2024/07/nvos-stock-earnings-novo-integrated-sciences-for-q3-of-2024/">jumping Friday on earnings</a>.</li>



<li><strong>Safe &amp; Green Development</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/"><strong>SGD</strong></a>) stock is sliding over 13% on Monday morning.</li>



<li><strong>Ryanair </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ryaay-stock-quote/"><strong>RYAAY</strong></a>) shares are falling more than 13% alongside <a href="https://www.cnbc.com/2024/07/22/ryanair-q1-2024-results-shares-fall-on-lower-fares-fall-in-quarterly-profit.html">falling quarterly profit</a>.</li>



<li><strong>Portage Biotech</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/"><strong>PRTG</strong></a>) stock is dropping over 11% on Monday.</li>



<li><strong>Stronghold Digital Mining</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdig-stock-quote/"><strong>SDIG</strong></a>) shares are decreasing more than 11% this morning.</li>



<li><strong>60 Degrees</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/"><strong>SXTP</strong></a>) stock is slipping over 10% on Monday morning.</li>



<li><strong>PS International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares close out our pre-market stock movers down almost 10% on Monday.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Society Pass</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sopa-stock-quote/"><strong>SOPA</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Society Pass reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -83 cents.</li><li>The company reported revenue of $1.71 million.</li><li>This was 23.96% worse than the analyst estimate for revenue of $2.25 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/sopa-stock-earnings-society-pass-for-q2-of-2024/">SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Allen Klee maintained a Hold rating on Society Pass (SOPA – Research Report) yesterday. The company's shares closed yesterday a...

Maxim Group Sticks to Its Hold Rating for Society Pass (SOPA)

ADIL

BLRX

CISO

CRWD

LIFE

NCPL

NUZE

NVDA

NVOS

PRTG

PSIG

RELI

RYAAY

SDIG

SERV

SNOA

SNTG

SOPA

SXTP

TELL

TELZ

XCUR

Press Releases

Society Pass Inc. (Nasdaq: SOPA)/Thoughtful Media Group Inc (TMG): Greenridge Global Initiates Equity Research Coverage on TMG; TMG To Capture Significant Advertising Market Share In Southeast Asia

Society Pass Inc. (Nasdaq: SOPA): Litchfield Hills Initiates Equity Research Coverage; SOPA Growing Rapidly and Nearing Positive EBITDA Inflection

Society Pass Inc. (Nasdaq: SOPA) 1Q 2024 Shareholder Update and Analyst Recommendations

Small Cap

Opinion

Thinking about buying stock in Certara, Stronghold Digital Mining, Society Pass, AgriFORCE Growing Systems, or Luxurban Hotels?

Financing

Society Pass Inc. Issues First Advance Notice to Strattners Bank, to Continue its Growth Plans

Society Pass Incorporated Announces 1-for-15 Reverse Split

Society Pass Set to Unlock and Monetize Current and Future Subsidiary Spin-Off Opportunities Through Strong and Flexible Financing

Society Pass Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Ascendiant Capital publishes a company update on Society Pass (NASDAQ: SOPA), expecting strong growth over the next year

IPOs

Society Pass Inc. Bolstering Subsidiaries Ahead of IPOs to Drive Growth and Customer Engagement

Comments

Society Pass

Society Pass (SOPA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO